A prospective trial of gastrointestinal cancer patients showed the feasibility of preemptive genetic testing for DPYD/UGT1A1 variants associated with increased chemotherapy toxicity. Genotype-guided ...
National clinical guidelines don’t mention screening cancer patients for DPYD gene variants, but hospital pharmacy leaders are forging ahead with the patient safety practice, the American Society of ...
DPYD, From Guidelines to Go-Live: Implementing Testing in the Lab, Upcoming Webinar Hosted by Xtalks
In this free webinar, see how DPYD testing can be implemented from guidelines to go-live through practical pharmacogenomics (PGx) reporting and workflow design. The featured speakers will share ...
Genomic medicine leverages an individual’s genetic information to guide healthcare decisions, with drug-gene testing (also known as pharmacogenomics, or PGx) being a key application that personalizes ...
Please provide your email address to receive an email when new articles are posted on . Genetic testing can be accomplished for most patients with gastrointestinal cancer prior to starting ...
FDA labeling now recommends DPYD variant testing before initiating capecitabine or 5-FU, except when immediate treatment is clinically necessary. Complete DPD deficiency markedly impairs 5-FU ...
Utilizing EMR capabilities to improve shared decision-making regarding DPYD pharmacogenomic testing.
Reducing defects in the medication use process for intravesicular chemotherapy in an academic ambulatory oncology infusion center. This is an ASCO Meeting Abstract from the 2025 ASCO Quality Care ...
Genetic testing of gastrointestinal cancer patients prior to starting chemotherapy proved feasible in a prospective study and showed a signal for a reduced risk of serious side effects. Compared with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results